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Mycophenolic acid antagonizes the activation of cultured hu- types I and III in addition to normal mesangial matrix
man mesangial cells. constituents such as collagen IV [1]. In culture condi-
Background. Activation of mesangial cells is observed in tions, mesangial cells display an activated phenotypeseveral forms of chronic renal disease, and in culture conditions
[2–4] with a high rate of proliferation in the presence ofupon stimulation by fetal calf serum (FCS), or agonists such
fetal calf serum (FCS), and the synthesis of collagen typeas transforming growth factor beta (TGF-). Mycophenolate
mofetil (MMF), the precursor of mycophenolic acid (MPA), I and other matrix proteins such as fibronectin [4] as
is currently used in organ transplantation and has been shown well as enhanced expression of smooth muscle -actin
to be protective in clinical and experimental glomerulonephri- (SMA). Stephenson et al have shown that the de novotis. This study assessed the effects of MPA on markers of
expression of SMA by cultured mesangial cells is nothuman mesangial cells (HMC) activation.
dependent on the rate of proliferation, but reflectsMethods. Primary cultures of HMC and of an immortalized
HMC clone (IP15 cells characterized in this report) were stimu- mainly cellular hypertrophy rather than hyperplasia [5].
lated either by FCS or by TGF-, and treated by MPA at Mesangial cell activation, a crucial event in the pathogen-
clinically relevant concentrations (1 to 10 mol/L) for 24 hours esis of renal fibrosis, may be modulated in vivo by differ-to 14 days. HMC proliferation, smooth muscle alpha-actin
ent types of stimuli, such as glomerular hypertension, or(SMA), collagen type I alpha-1 chain (coll I) and fibronectin
inflammatory phenomena depending on the accumula-synthesis were used as markers of HMC phenotypic activation.
Results. Exposure of HMC to MPA inhibited proliferation tion of immunocompetent cytokine-secreting cells [1].
induced by FCS without cytotoxicity. MPA counteracted the Among the various cytokines and autacoids involved
stimulatory effects of FCS and TGF- on coll I mRNA and in the pathophysiology of glomerular fibrosis, trans-protein and fibronectin protein. SMA expression was increased
forming growth factor- (TGF-) is a prominent factor.upon exposure to MPA, without cell hypertrophy.
Conclusion. Treatment of cultured HMC with MPA inhib- TGF-1 mRNA has been documented in normal rat
ited mesangial cell proliferation and matrix production induced glomeruli and tubules, with the presence of both types of
by stimulation with either FCS or TGF-. Such mechanisms receptors to TGF-. TGF- is expressed in experimental
may contribute to the favorable effects of treatment using
and clinical nephropathies characterized by renal fibrosismycophenolate mofetil in chronic fibrotic kidney diseases, in-
[2, 3]. It has a major role in the increase of extracellularcluding chronic allograft rejection.
matrix deposition as it increases the synthesis of matrix
components, reduces their degradation, and enhances
the integrin expression that facilitates matrix assembly.Progressive sclerosis of glomeruli is the common path-
TGF- may be overproduced by infiltrating leukocytesway of several forms of renal disease, which all result in
and by resident renal cells, including mesangial cells.the activation of mesangial cells and an excessive accu-
Stimulation of mesangial cells by TGF- induces an in-mulation of matrix proteins. Activated mesangial cells
creased synthesis of various matrix proteins includingcan be shown to be proliferating with an increase of
collagen type I [4], increases the expression of SMA bythe production of interstitial collagens, mainly collagen
mesangial cells, decreases cell proliferation, and stimu-
lates cell hypertrophy [3, 5]. Given the pivotal role ofKey words: collagen, fibronectin, smooth muscle -actin, immunosup-
TGF- in the pathophysiology of fibrotic renal diseases,pression, chronic allograft rejection, progressive glomerulosclerosis,
organ transplantation. antagonizing its effects may be renoprotective in experi-
mental and human nephropathies.Received for publication January 8, 2002
Mycophenolic acid (MPA) is a reversible inhibitor ofand in revised form February 22, 2002
Accepted for publication April 10, 2002 the inosine monophosphate dehydrogenase, an enzyme
responsible for the de novo synthesis of guanosine [6]. 2002 by the International Society of Nephrology
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The precursor of MPA, mycophenolate mofetil (MMF), tioned). Mycophenolic acid (MPA) was kindly provided
is currently used for immunosuppression after organ by Roche (Palo Alto, CA, USA); a stock solution of
transplantation [6, 7]. MPA inhibits leukocyte prolifera- 1 mmol/L was made by solubilization in methanol and
tion by guanosine depletion, and the capacity of leuko- stored in aliquots at 20C. For culture experiments,
cytes to invade tissular areas of inflammation [8]. This dilutions were made in culture medium to yield final
latter effect is due to an inhibition of glycosylation and concentrations of 0.001 to 10 mol/L MPA. Control cells
expression of membrane glycoproteins that are members were treated with culture medium containing vehicle
of adhesion molecules involved in cell migration [9]. (0.1% methanol). Monoclonal antibodies against human
The immunosuppressive properties of MMF have lead smooth muscle -actin (1A4 clone), collagen type I
to its clinical utilization in various types of glomerulone- (COL-1 clone), vimentin (VIM-132 clone) and cellular
phritis [10], including lupus nephritis [11–13] and others fibronectin (FN-3E2 clone) were from Sigma Chemical
for which preliminary observations have been published (St. Louis, MO, USA).
[11, 14–16]. MMF also has been used in various models
Isolation and culture of human mesangial cellsof experimental nephropathies. A protective effect of
MMF has been demonstrated in immune glomerulone- Human mesangial cells (HMC) were isolated from a
phritis that may be related to its immunosuppressive piece of normal renal cortex obtained during nephrec-
properties [17–21]. In the rat remnant kidney after 5/6 tomy in patients with kidney tumors. Briefly, renal cortex
renal ablation, several groups have shown that interstitial was minced in culture medium, and small fragments were
myofibroblast infiltration was reduced and renal function pushed through a 180-m stainless steel mesh with a
preserved after treatment with MMF [22–24]. Further- glass pestle. Isolated glomeruli were collected onto a
more, a synergistic effect between MMF and losartan 110 m sieve, resuspended in culture medium, and pel-
has been shown in the same model [25]. In most studies, leted by one minute of centrifugation at 1000 rpm. They
MMF treatment reduced the infiltration of macrophages were then incubated with type I collagenase (1 mg/mL)
and lymphocytes, and the expression of adhesion mole- for 30 minutes at 37C with gentle agitation, which re-
cules involved in the infiltration of inflammatory cells, sulted in digestion of glomerular basement membrane
including intracellular adhesion molecule-1 (ICAM-1) and shedding of epithelial cells; glomerular remnants,
and lymphocyte function associated antigen-1 (LFA-1) consisting mainly of mesangial and endothelial cells,
[25–28]. Therefore, a major factor contributing to the were then collected onto a 80 m sieve, while single
protection of renal function by MMF treatment in these cells were eliminated by extensive rinsing with culture
models depends on its action on leukocytes. medium. Glomeruli were then plated into culture dishes
However, MMF may have direct effects on mesangial
and the first cellular outgrowth was usually observed bycells, as shown by Ziswiler et al in the anti-Thy-1 nephri-
day 3 of culture.tis model, in which treatment by MMF significantly re-
Cells were grown in RPMI 1640 medium supple-duced glomerular mesangial proliferation and matrix de-
mented with 10% fetal calf serum (FCS), antibiotics (100position [29]. The hypothesis of a direct effect of MMF on
U/mL penicillin and 100 g/mL streptomycin), Na py-mesangial cell phenotype is supported by experimental
ruvate, non-essential amino acids, and 1 mmol/L Hepesresults such as a dose-dependent inhibitory effect of
buffer. This medium allowed selective growth of mesan-MPA on rat and human mesangial cell proliferation,
gial cells, and cultures were free of other cell types afterwhich is mediated by guanosine depletion [29, 30]. Fur-
the third passage. This was assessed for each culturethermore, MPA inhibits PDGF-induced mesangial se-
by immunohistochemistry showing positive labeling forcretion of osteopontin, an extracellular matrix glycopro-
smooth muscle -actin and vimentin, and negative label-tein involved in the pathogenesis of glomerular sclerosis
ing for cytokeratin, von Willebrand factor or smooth-[31].
muscle myosin heavy chain. Fibroblast contaminationIn the present study we hypothesized that MPA could
was excluded by the ability of the cells to grow inantagonize the activation of cultured human mesangial
D-valine containing selective medium.cells (HMC) resulting from exposure to FCS or from
Isolation of an immortalized mesangial clone. Thestimulation by TGF-. Markers of activated mesangial
cells used in this study were derived from different do-cells have been evaluated, including mitogenic activity,
nors. In one culture, cells at the third passage were main-smooth muscle -actin expression, and collagen type I
tained for 24 hours in contact with retroviral particlesand fibronectin synthesis.
(murine leukemia virus, MLV) expressing the large T
antigen of SV40 and the neomycin resistance gene. After
METHODS one week in culture in the presence of geneticin (equiva-
Materials lent to 6418) 30 clones were isolated. Among them, one
clone (IP15) was selected that presented the morphologi-All products used for cell culture were obtained from
Gibco BRL (Cergy-Pontoise, France) (exceptions men- cal appearance of mesangial cells, that is, spindle-shaped
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cells with a hill and valley type of organization at high species can be individualized by electrophoresis. The
cellular density. IP15 cells were maintained in culture collagen I 1 cDNA probe was a kind gift from Dr. Le
for up to 40 passages with stable characteristics, including Guellec (Lyon, France) [32], and consists of a 766 bp
neomycin resistance, contractile response to angiotensin Sac I/Eco RI fragment subcloned into Bluescript pKS.
II (data not shown), and expression of SMA, collagen Total RNA was isolated from confluent cells grown
type I and fibronectin (data not shown). The prolifera- in 100 mm culture dishes using the method of Chomczyn-
tion rate of IP15 cells was two to three times higher than ski and Sacchi [33]. After electrophoresis through a 1%
that of other cultures used at earlier (4th to 7th) passages. agarose gel containing 3% formaldehyde, the RNA was
transferred onto a nylon membrane (Immobilon Ny,
Cell proliferation assays Millipore). The four-hour prehybridization and over-
Direct cell counting. Mesangial cells were plated onto night hybridization periods were performed at 42C as
24-well plates at an identical density (104 cells/cm2). After previously described. The probes were 32P-labeled using
a four-hour adhesion period, unbound cells were dis- the random priming labeling kit from Amersham (Pisca-
carded and adherent cells from four wells were trypsin- taway, NJ, USA). After hybridization, the blots were
ized and counted (day 0 point) using a Coulter apparatus washed under stringent conditions and exposed to a Ko-
(Coulter Channelyzer 256; Beckman Coulter, Villepinte, dak film at 80C for 24 to 72 hours. Autoradiograms
France). At the same time, the medium was changed in were digitized using a Sony digital camera and densito-
the other wells for fresh medium containing the different metric analysis was performed using the NIH Image 1.62
agonists tested. Three days later, the cells were trypsin- program for Macintosh.
ized and counted using the Coulter apparatus (day 3
point). Proliferation rate was reported as the ratio of Western blot
day 3/day 0 cell numbers. Total proteins were extracted from mesangial cells
Proliferation assay. Mesangial cells were plated onto lysed in buffer containing 0.3% sodium dodecyl sulfate
96-well plates at an identical density (3000 cells/well). (SDS), 1% -mercaptoethanol, 0.1% DNAse, 0.2%
After the four-hour attachment period, the medium was RNAse, and protease inhibitors [1 mmol/L phenylmeth-
changed for fresh control or MPA (1 mol/L) medium, ylsulfonyl fluoride PMSF), 1 mmol/L leupeptin]. The
and cells were cultured for three days. Then the cells lysate was scraped from the culture dish, and protein
were rinsed with phosphate-buffered saline (PBS), and content was measured using the Bradford protein assay
100 L of fresh medium were dispensed in each well. (Bio-Rad, Richmond, CA, USA). After protein reduc-
The cells were incubated at 37C for four hours before
tion into the Laemmli buffer, samples were kept atthe addition of 20 L of Cell Titer 96 AQueous Reagent
80C until use. Equal amounts of total proteins were(Promega, Madison, WI, USA). This reagent is a tetrazo-
boiled for five minutes before loading on SDS-polyacryl-lium compound that is reduced by dehydrogenase en-
amide gel electrophoresis (SDS-PAGE). After electro-zymes present in metabolically active cells. After a two-
phoresis, proteins were transferred onto polyvinylidenehour incubation period, the absorbance at 492 nm was
difluoride (PVDF) membranes (Immobilon P; Millipore,measured using a 96-well plate reader (Titertek Multiscan
Bedford, MA, USA). Membranes were then blockedMC; Flow Laboratories, Paris, France). This absorbance
with 5% non-fat dry milk in Tris-buffered saline (TBS)measures the quantity of Formazan (Promega) pro-
containing 0.05% Tween 20 for one hour at room tem-duced, which is proportional to the number of viable cells
perature, followed by overnight incubation at 4C withpresent in each well.
the primary antibody (diluted in blocking buffer at the
following ratios: SMA, 1/5000; collagen type I, 1/500;RNA isolation and Northern-blot
vimentin, 1/2000; cellular fibronectin, 1/5000). AfterThe actin probe used for Northern blot hybridization
washing with TBS-Tween containing 1% dry milk, thewas prepared by polymerase chain reaction (PCR) am-
membranes were incubated with the second antibodyplification of human mesangial cDNA. The oligonucleo-
(antimouse IgG conjugated with horseradish peroxidase;tides used for actin amplification gave a DNA fragment
Immunotech, Narseilla, France) for one hour at roomof 1207 base pairs, which corresponds to bases 42 to 1248
temperature. Immunoreactive bands were detected withof the human smooth muscle -actin mRNA sequence
enhanced chemiluminescence (ECL) according to manu-(Genbank reference number, X13839). The PCR prod-
facturer’s recommendations (Amersham, Little Chal-uct was cloned into the pGEMT vector (Promega) and
font, Buckinghamshire, UK).characterized by sequencing. Since this sequence share
82% homology with the -actin transcript (Genbank ref-
Immunolabelingerence number, X00351), the probe recognizes both
Immunolabeling was performed on IP15 cells culturedmRNAs species when used for Northern blot analysis.
onto 2-well glass slides (Falcon; Becton Dickinson, Mey-Nevertheless, the -actin transcript is 400 bp longer than
the SMA actin transcript, and thus the two actin mRNA lan, France). At the end of the culture period, cells were
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rinsed in PBS, fixed 10 minutes into 3% paraformalde-
hyde, and permeabilized for three minutes in 0.1% Tri-
ton. Endogenous peroxidase was inactivated with 0.3%
H2O2 for 30 minutes, and non-specific antibody sites were
blocked by preincubation with 5% bovine serum albu-
min (BSA) diluted in PBS for 20 minutes. The mono-
clonal antibody specific to SMA was diluted 1/500 in a
solution of 1% BSA in PBS, and the cells were incubated
with this solution for one hour at room temperature.
They were consecutively incubated with the biotinylated
secondary antibody (anti-mouse Ig; Amersham Life Sci-
ence) for one hour and streptavidin-horseradish peroxi-
dase complex (Amersham Life Science) for 30 minutes.
Peroxidase activity was revealed using diaminobenzidine
tetrahydrochloride and H2O2 for 15 minutes. Cell nuclei
were then counterstained with Mayer’s hemalum solu-
tion (Merck, Darmstadt, Germany), washed in water,
and cover slipped.
Statistical analysis
Results are expressed as mean SEM. Statistical anal-
yses on quantitative data were performed by analysis of
variance (ANOVA), and comparison of means was done
by the Scheffe´ test, using the Statview 5 software for
Macintosh. Data of distribution of cell diameter were
compared using the 2 analysis. For all experiments, P
values 	0.05 were considered significant. Non-linear re-
gression analysis and IC50 determination were performed
using the Origin software for Windows.
Fig. 1. Antiproliferative effects of mycophenolic acid (MPA) on hu-RESULTS
man mesangial cells. (A) Concentration-dependent inhibition of human
Reversible inhibitory effect of MPA on human mesangial cell proliferation by MPA. IP15 cells were seeded at identical
density (3000 cells/well) into 96-well plates and treated for 3 days withmesangial cell proliferation
various doses of MPA (0 to 10 mol/L). At the end of the incubation
Human mesangial cells were seeded on 96-well plates period, cells were incubated with the Cell Titer reagent following manu-
facturer’s recommendations. The graph represents absorbance at 492and allowed to proliferate for three days in culture
nm (proportional to the number of viable cells in the well) as a functionmedium containing 10% FCS, and in the absence or of MPA treatment. Data are mean  SE of a typical experiment with
presence of various concentrations of MPA. A concen- 8 replicate measurements. The IC50 was calculated using Boltzman’s
equation at 0.062  0.004 mol/L. This experiment was repeated usingtration-dependent inhibition of cell proliferation was ob-
IP15 and early-passage mesangial cells, with similar results. (B) Typicalserved using the cell titer proliferation assay: despite
experiment showing the reversible effect of MPA on mesangial cell
identical initial seeding density, the number of cells pres- proliferation rate. Human mesangial IP15 cells were cultured for 3 days
in the presence or absence (control) of 10 mol/L MPA, and seededent per well after three days in culture was lower with
at identical density (20,000 cells/well) in 24-well plates. After a four-increasing concentrations of MPA (Fig. 1A). This result
hour attachment period, adherent cells were counted (Day 0 point), and
was confirmed by direct cell counting (Fig. 1B). Using medium was changed for fresh control or MPA-containing 10 mol/L
medium. After 3 days, the cells were trypsinized and counted (Day 3either early-passage mesangial cells or the highly-prolif-
point), and the proliferation rate calculated as the Day 3/Day 0 ratio.erative IP15 clone, the maximal effect on inhibition of
This experiment presents the mean  SE of 3 experimental points per
cell proliferation was reached for 0.5 mol/L MPA, and condition. It was repeated twice using either IP15 cells or early-passage
mesangial cells, with similar results.calculated IC50 ranged from 0.056 to 0.072 mol/L MPA.
The cultures were maintained for up to 12 days in the
presence of 1 to 10mol/L MPA without any cell damage
MPA inhibits the production by human mesangial(not shown). Furthermore, when HMC that had been
cells of extracellular matrix components, fibronectincultured for three days in the presence of a high concen-
and collagen type Itration of MPA (10 mol/L) were re-exposed to culture
To explore the effects of MPA on mesangial extracel-medium with 10% FCS, the antiproliferative effects of
lular matrix deposition, we examined how MPA treat-MPA were rapidly reversible (Fig. 1B), indicating that
MPA was not cytotoxic. ment affects the expression levels of two main compo-
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Fig. 2. Western blot analysis of the effects
of MPA on fibronectin expression in human
mesangial cells. Lane A, fibronectin secretion
in culture medium. Early-passage mesangial
cells (lanes B and C) or IP15 cells (lanes D-F)
were treated with various doses of MPA (no
MPA in lanes B and D; 1 mol/L in lanes C
and E; 10 mol/L in lane F) for 5 days. Cul-
ture medium was collected, centrifuged 10
minutes at 1100 rpm to remove cellular debris,
and the supernatant prepared with Laemmli
buffer (Methods section). Thirty microliters
of each sample were analyzed by Western-blot
analysis using a monoclonal antibody directed
against cellular form of fibronectin. Thirty mi-
croliters of culture medium alone (without
contact with the cells, lane A) was deposited
in parallel, to assess the absence of reaction
between the antibody and serum fibronectin
present in the culture medium. (B) Fibronec-
tin present in the cell lysates. IP15 cells were
cultured for 3 days in the absence or in the
presence of 0.01 to 1 mol/L MPA, and 30 g
of each cell lysate were deposited onto 8%
acrylamide gel. Western blot analysis was per-
formed using the same antibody as in panel A.
When equal protein amounts of cell lysates were ana-
lyzed by Western blot with the same antibody, fibronec-
tin expression was lowered in a dose-dependent way,
the maximal effect being obtained with 1 mol/L MPA.
Increasing MPA concentration to 10 mol/L did not
induce a further lowering of fibronectin secretion (data
not shown).
The media samples also were analyzed by Western
Fig. 3. Western-blot analysis of the effects of MPA on collagen type
blot for collagen type I. The antibody, specific for theI expression in human mesangial IP15 cells. IP15 cells were treated
with 1 to 10 mol/L MPA for 5 days. Culture medium (30 L) was 1 chain of human collagen type I, recognizes the 140-kD
analyzed by Western blot analysis using a monoclonal antibody directed pro--1 and the 120-kD -1 forms (Fig. 3). No collagen
against the 1 chain of collagen type I. Thirty microliters of culture
type I was detected in the culture medium. As for fibro-medium alone (without contact with the cells) was deposited in parallel,
to assess the absence of reaction between the antibody and serum nectin, we observed a decrease in collagen type I secre-
components. tion by cells cultured in the presence of MPA.
The MPA-induced decrease in collagen type I secre-
tion could be attributed at least in part to a decrease in
the corresponding mRNA level, as evidenced by North-nents of the pathological mesangial matrix, fibronectin
ern blot analysis (Fig. 4). A five-day treatment withand collagen type I, which are both synthesized by HMC
1 mol/L MPA resulted in a dramatic alteration in thein vitro. Early-passage cells or IP15 cells were treated
1 Col I/GAPDH mRNA ratio (80%, Fig. 4). How-for five days with various concentrations of MPA, the
ever, this down-regulation was delayed. No noticeablemedia being changed once on the third day. Thus, the
change in 1 Col I mRNA relative expression level wasmedium was collected for Western blot analysis after 48
observed after 24 or 48 hours of MPA treatment (datahours in the presence of treated or non-treated cells.
not shown).In all conditions tested, staining with an antibody spe-
cific for the human cellular form of fibronectin revealed
MPA increases the expression of -smooth actin intwo main bands with typical molecular weights of 220
human mesangial cellsto 240 kD, but no cross-reaction with this form of fibro-
Treatment of IP15 cells for three days with 1 mol/Lnectin that was present in the serum added to the culture
MPA days led to an increase in the expression level ofmedium (Fig. 2A). In both early-passage mesangial cells
SMA detectable by immunolabeling (Fig. 5). Despite aor the IP15 clone, MPA decreased the level of fibronectin
much lower cell density, the intensity of actin labelingsecreted in the culture medium. MPA had the same
inhibitory effect on cell-associated fibronectin (Fig. 2B). (revealed as a brown staining) appears to be higher in
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phenotype of HMC, by increasing the cell size, inducing
the production of ECM components and the expression
of SMA. Considering the deleterious consequence on
the progression of glomerular fibrosis, it was important
to assess the impact of MPA on the phenotypical changes
of HMC induced by TGF-.
Since TGF- is a potent stimulator of collagen I pro-
duction, we tested the interaction between TGF- and
MPA. IP15 cells were treated for three days with
1 mol/L MPA alone, and for MPA plus or minus 5
ng/mL TGF- for two additional days. TGF- increased
the release of collagen by HMC, and its effect was still
observable, but to a much lower extent, in the presenceFig. 4. Northern-blot analysis of the effects of MPA and TGF- on
collagen type I expression in human mesangial cells. IP15 cells were of MPA (Fig. 7). As observed at the protein level, TGF-
treated without (Control) or with 1 mol/L MPA for 5 days, and in stimulated relative 1 Col I mRNA expression by 100%the presence or absence of 5 ng/mL TGF- (TGF) for the last 48 hours.
in both non-treated or MPA-treated cells, but the tran-Fifteen micrograms of total RNA were deposited on a 1% denaturing
agarose gel and subjected to Northern blot analysis using 32P-labeled script amount in the presence of both MPA and TGF-
probes specific to human 1 chain of collagen type I or GAPDH. was lower than in the presence of TGF- alone (72%;
Fig. 4).
Smooth muscle -actin expression was increased when
cells treated with MPA. Incubation experiments with HMC were cultured in the absence of serum or after
increasing doses of MPA and subsequent analysis of stimulation by TGF-, two conditions that inhibit cell
protein expression by Western blot analysis revealed that proliferation and promote cell hypertrophy [5, 34]. The
this effect was dose-dependent, maximal SMA expres- effect of MPA on mesangial cell size was investigated
sion being reached in the presence of 0.2 mol/L MPA by analyzing cell diameter with the Coulter Channelizer
(Fig. 6A). Similar results were observed with MPA- cell counter. IP15 cells were cultured for three days in the
treated early-passage cells (Fig. 6B), showing that this
presence or absence of 5 ng/mL TGF- and/or 1 mol/Leffect was not specific to the IP15 clone. The high expres-
MPA, harvested by trypsinization and analyzed usingsion level of SMA remained stable with time and was
forward light scatter mode. Figure 8 shows the distribu-observed for up to 12 days of treatment (data not shown).
tion of mesangial cell diameter under each culture condi-Northern blot analysis of RNAs extracted from IP15
tion. As expected, HMC cultured in the presence ofcells showed an increase of the SMA/-actin transcript
TGF- were larger than non-treated cells (2 test; P 	ratio that was dose-dependent, and observable as early
0.001). The addition of MPA to the culture medium hadas 24 hours of cell stimulation by MPA (Fig. 6C). Quanti-
no effect on cell size, but did not prevent the hypertrophytation of alpha and beta actin signals was performed on
caused by TGF-.three different Northern blots, using mRNAs extracted
Transforming growth factor- has been reported tofrom IP15 cells at three different passages. The / actin
cause an increase of mesangial SMA expression corre-ratio were (in arbitrary units): untreated cells, 0.88 
lated to cell hypertrophy [5]. Since MPA increased SMA0.11; cells treated by 1 mol/L MPA for 24 hours, 1.18 
expression without causing cell hypertrophy (Figs. 6 and0.18; cells treated by 1 mol/L MPA for 48 hours,
8), we compared the effects of MPA and TGF- treat-1.82  0.33 (P 	 0.05 vs. untreated cells). Extending the
ments on SMA. IP15 cells cultured in the presence orMPA treatment to 5 (Fig. 6C), 10 or 14 days (not shown)
absence of 1 mol/L MPA were treated with 5 ng/mLdid not induce further changes of the expression level
TGF- for two days. Western blot analysis of the proteinof SMA: the / actin ratio were 1.75, 1.7 and 1.67 after
extracts showed that TGF- stimulated SMA expression5, 10 and 14 days, respectively (one experiment each).
in mesangial cells, with an intensity similar to that ob-Finally, we also observed that the stimulation of SMA
expression by MPA was reversible: when IP15 cells were served in the presence of MPA (Fig. 9). Moreover, the
cultured for one week in the presence of 1 mol/L MPA, combination of TGF- and MPA treatments induced
and then for two days in the absence of MPA, the / cell hypertrophy (Fig. 8), but did not increase SMA ex-
actin mRNA ratio was 0.9  0.18, a value that was not pression when compared to MPA treatment alone
different from that observed in non-treated cells (data (Fig. 9). Therefore, TGF- and SMA had no synergistic
from 2 different cultures). effect on the expression of SMA.
Interactions of MPA with the TGF-–induced
DISCUSSIONphenotype of human mesangial cells
The present study found that MPA inhibited FCS-It has been shown previously that transforming growth
factor- (TGF-) exerts a profound influence on the induced HMC proliferation, as previously described by
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Fig. 5. Immunostaining for -smooth muscle actin in control and MPA-treated human mesangial cells. IP15 cells were seeded at identical density
in 2-well Lab Tek chambers and cultured for 3 days in the absence (A) or presence (B) of 1 mol/L MPA (
200).
Fig. 6. Effects of MPA on -smooth actin
expression in human mesangial cells: Western
blot and Northern blot analyses. (A) Western
blot analysis of the dose-dependent increase in
mesangial -smooth actin (SMA) expression.
IP15 cells were cultured for 3 days in the ab-
sence or in the presence of 0.01 to 1 mol/L
MPA, and 30 g of each cell lysate were de-
posited onto 8% acrylamide gel (same extracts
used in Fig. 2B). SMA appears as a 45 kD
band. The same membrane was then reprobed
with an anti-vimentin (58 kD) antibody to as-
sess equal protein amount in each sample. (B)
Western blot analysis of SMA expression in
early-passage human mesangial cells cultured
for 3 days in the absence (Control) or presence
of 1 mol/L MPA. (C ) Dose-dependent and
time-dependent increase in SMA mRNA in
IP15 cells treated by MPA. Cells were cultured
for 3 days in the presence of various doses of
MPA, or for 1 or 5 days in the presence of 1
mol/L MPA. Ten micrograms of total RNA
were deposited onto a 1% agarose denaturing
gel. Northern blot analysis using a 32P-labeled
actin probe revealed both -actin and -
smooth muscle actin.
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renal cells, particularly interstitial myofibroblasts, tubu-
lar cells and mesangial cells [22–24, 29, 30, 36]. At vari-
ance with the effect of TGF-, MPA had no effect on
cell size, that is, it did not induce cell hypertrophy (dis-
cussed later in this article). From these results, it is clear
that a major part of the renoprotective action of MMF
is mediated through the inhibition of cell proliferation.
Our results show that MPA exerts a direct inhibitory
effect on the secretion of fibronectin and collagen type IFig. 7. Interaction between MPA and TGF- on the regulation of
collagen a1(I) chain secretion by human mesangial cells. IP15 cells were 1 chain by HMC (Figs. 2 to 4). Mesangial cells cultured
treated with 1 to 10 mol/L MPA for 5 days, and with 5 ng/mL TGF- in the presence of FCS secrete high amounts of fibronec-
for the last 48 hours. Collagen type I secreted in the culture medium
tin and collagen type I [37], which is a hallmark of theirunder each culture condition was analyzed by Western blot as described
in Figure 3. “activated/dedifferentiated” phenotype [38].
Mycophenolic acid lowered collagen 1(I) chain basal
transcription and transduction by IP15 cells, and attenu-
ated the stimulatory effect of TGF- on collagen syn-
others [30]. Furthermore, MPA had a stimulatory effect on thesis at clinically attainable concentrations of 1 and
SMA expression, and decreased FCS and TGF-–induced 10 mol/L. In cultured rat mesangial cells, Ziswiler et
synthesis of fibronectin and collagen type I. These results
al did not observe any effect of MPA on the expression
suggest that MPA has intrinsic anti-fibrotic properties
of mRNAs encoding fibronectin, collagen type I 2 orthat could be therapeutically useful in the treatment of
collagen type IV 1 chains [29]. The discrepancies be-several forms of chronic glomerulonephritis.
tween our results and those of Ziswiler et al may beIn most of the experiments reported in this study, we
explained by interspecies differences, or by differenceshave used a clone of transformed mesangial cells isolated
in the regulation of the expression of genes encoding 1in our laboratory (IP15 cells). As a matter of fact, the
and 2 chains of collagen type I, or in the duration ofutilization of human mesangial cells is hampered by their
MPA treatment: Ziswiler et al analyzed mRNA accumu-limited survival span and their dedifferentiation in cul-
lation after only two days of culture in the presence ofture. To avoid this problem, we established a stable im-
MPA, while our study showed a significant decrease inmortalized human cell. These cells were used at late
collagen I 1 mRNA after five days but not after onepassages, but had most of the properties of mesangial
or two days of treatment. The reason for this delay incells in primary culture. When cultured in the presence
gene inhibition is not known, but this observation raisesof 10% FCS, they expressed markers of activated and
the possibility of a role for guanosine-5-triphosphatededifferentiated mesangial cells, that is, expression of
(GTP)-dependent processes in the regulation of collagenSMA (Fig. 4), and secretion of collagen type I, which
1 chain gene expression: Mucsi et al have shown thatwere both stimulated by TGF- (Figs. 4, 7, and 9). MPA
part of the effects of TGF- are mediated by small Gexerted a concentration-dependent inhibition of the pro-
proteins such as Rac [39], while specific inhibition ofliferative response of IP15 cells to serum mitogens. The
Rho, another guanosine 5-triphosphate (GTP)-bindingsensitivity of IP15 cells to the inhibitory effect of MPA
protein, lowered collagen type I accumulation in hepaticwas similar to that of HMC used at early passages, which
myofibroblasts [40]. Therefore, the inhibitory effect ofshowed a maximal inhibition of 3H-thymidine incorpora-
MPA on collagen synthesis may be mediated, at least intion at a concentration of 0.6 mol/L [30]. Even after
part, by GTP depletion of HMC. No study of the time-two weeks of treatment, no evidence of necrosis or apo-
course decrease in guanine nucleotide levels in responseptosis was observed. Moreover, the reversibility of IP15
to MPA treatment has been published in mesangial cells;proliferation inhibition is in accordance with previous in
however, in endothelial cells, a 48 hour MPA treatmentvitro observations on human [30] and rat [29] mesangial
is necessary to achieve a 50% decrease in intracellularcells.
GTP [41].The inhibitory effect of MPA on FCS-induced HMC
The rate of spontaneous synthesis of fibronectin pro-proliferation reported in this study and others [30] is not
duction by HMC and IP15 cells cultured with FCS wasrestricted to this cell type, since a similar action has been
lowered upon exposure to MPA. These data indicatedocumented in vitro in vascular smooth muscle cells [35]
that the inhibition of fibrosis by MMF treatment in vivoand in rat fibroblasts [23]. MPA inhibition of prolifera-
does not depend exclusively on the lowering of collagention was reversible, suggesting that it was not cytotoxic,
type I synthesis, but that other matrix proteins mighta relevant finding in the perspective of its clinical use.
be influenced by MMF. In fact, osteopontin is anotherIn most studies of experimental nephropathies, treat-
ment by MMF decreased the proliferation of resident extracellular matrix component where its expression has
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Fig. 8. Effects of MPA and/or TGF- on the distribution of mesangial cell size. IP15 cells were cultured for 3 days in the absence (Control) or
presence (MPA) of 1 mol/L MPA, and for the last 48 hours in the presence (TGF-, dotted lines) or absence of 5 ng/mL of TGF-. Cells were
then dissociated using trypsin, resuspended and counted using the Coulter Channelizer apparatus, which measured the diameter of each cell. The
diagram shows the repartition of the cell populations as a function of cell diameter.
et al have shown that in mouse mesangial cells, SMA
expression was higher in cells at early passages and with
a low proliferation rate [42]. Therefore, increased SMA
expression in mesangial cells may not be equivalent to
a state of dedifferentiation, since mesangial cells express
SMA in normal conditions in vivo [42] and since in cer-
tain culture conditions, such as exposure of HMC to MPA
as in our study, increased SMA expression is associated
to a more differentiated phenotype. Transcriptional reg-
Fig. 9. Smooth muscle -actin expression in IP15 cells treated by MPA
ulation of the SMA gene is complex and depends onor TGF-. IP15 cells were cultured for 5 days in the presence of 1mol/L
MPA and/or for 48 hours in the presence of 5 ng/mL TGF-. Western several positive and negative cis-acting elements located
blot analysis of SMA expression was performed as described in Fig- in the promoter region or within the first intron [43, 44].
ure 6A.
Stephenson et al have suggested that serum may contain
unidentified factors that down-regulate SMA expression,
and/or other substances (such as PDGF) that may en-
hance TGF- responsiveness [5]. If this is so, then webeen shown to be decreased by MPA treatment of mes-
angial cells [31]. speculate that MPA counteracts the effects of these fac-
tors by a mechanism that remains to be elucidated.We used therapeutically relevant concentrations of
MPA (1 to 10 mol/L) to characterize its effects on
Conclusionmarkers of mesangial activation. MPA significantly in-
creased SMA expression in both early-passage or IP15 The present study shows that chronic (4 to 14 days)
treatment of cultured HMC with MPA at clinically rele-HMC. This stimulation was effective at both mRNA
and protein levels, as long as exposure to MPA was vant concentrations (1 to 10 mol/L) prevented mesan-
gial proliferation without cytotoxic effects and the phe-maintained, but was reversible when MPA was removed
from the culture medium. It is noteworthy that the maxi- notypic modifications that lead to excessive matrix
production after stimulation by FCS or TGF-. Inhibi-mal effect on SMA expression was obtained at doses
that also exert a maximal inhibitory effect on cell prolif- tion of mesangial cell proliferation and matrix produc-
tion by MPA might contribute to the favorable effectseration (0.2 to 0.5 mol/L).
At variance with TGF-, MPA induces mesangial of mycophenolate mofetil in chronic fibrotic kidney dis-
eases, including chronic allograft rejection.SMA expression but not cellular hypertrophy. Iehara
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